Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958552 | 0.84 | CNOT7 (0.33) | ALDH1A1CNOT7MAPTKMT2AHSD17B10 | |
| SCHEMBL20674230 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KDM4ECNOT7TDP1MAPT | |
| SCHEMBL20631038 | 0.80 | KMT2A (0.40) | ALDH1A1KDM4ETDP1MAPTCYP2C9 | |
| SCHEMBL20631054 | 0.74 | CNOT7 (0.33) | KDM4ECNOT7PKM | |
| SCHEMBL21958535 | 0.70 | CNOT7 (0.33) | ALDH1A1KDM4ECNOT7PKM | |
| SCHEMBL20631036 | 0.69 | LMNA (0.36) | KDM4EKMT2APKMHSD17B10 | |
| SCHEMBL21958543 | 0.67 | CNOT7 (0.30) | CNOT7 | |
| SCHEMBL20631043 | 0.67 | DDB1 (0.32) | CNOT7 | |
| SCHEMBL21958544 | 0.67 | CNOT7 (0.30) | CNOT7 | |
| SCHEMBL20631059 | 0.67 | KDM4E (0.35) | ALDH1A1KDM4ETDP1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | ALDH1A1 3098/4885KDM4E 1912/4885CNOT7 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.